Regeneron Pharmaceuticals Inc (REGN)

Debt-to-equity ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Long-term debt	US$ in thousands	1,984,400	1,984,000	1,983,600	1,983,300	1,982,900	1,982,600	1,982,200	1,981,800	1,981,400	1,981,100	1,980,700	1,980,400	1,980,000	1,979,600	1,979,200	1,978,900	1,978,500	1,978,300	—	—
Total stockholders’ equity	US$ in thousands	29,353,600	29,325,900	28,205,800	26,991,100	25,973,100	24,904,400	24,017,900	23,495,200	22,664,000	21,438,800	20,687,800	19,914,700	18,768,800	17,258,000	15,127,300	11,977,000	11,025,300	10,125,500	9,057,400	12,133,000
Debt-to-equity ratio		0.07	0.07	0.07	0.07	0.08	0.08	0.08	0.08	0.09	0.09	0.10	0.10	0.11	0.11	0.13	0.17	0.18	0.20	0.00	0.00

December 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $1,984,400K ÷ $29,353,600K
= 0.07

Regeneron Pharmaceuticals Inc has shown a declining trend in its debt-to-equity ratio over the years, based on the provided data. The ratio decreased from 0.20 as of September 30, 2020, to 0.07 as of December 31, 2024. This indicates that the company has been decreasing its reliance on debt financing in relation to equity over this period.

A decreasing debt-to-equity ratio can signal improved financial health and reduced financial risk for the company. It suggests that Regeneron Pharmaceuticals Inc may be managing its debt levels effectively while potentially leveraging more equity in its capital structure.

Overall, the declining trend in the debt-to-equity ratio for Regeneron Pharmaceuticals Inc implies a positive financial position in terms of debt management and may indicate strong performance in the company's capital structure management.